- 全部删除
您的购物车当前为空
Enzaplatovir (BTA-585) 是一种可口服的融合 (fusion) 抑制剂,具有抗病毒活性,可用于研究呼吸道合胞病毒感染和冠状病毒病 (COVID-19) 感染。

Enzaplatovir (BTA-585) 是一种可口服的融合 (fusion) 抑制剂,具有抗病毒活性,可用于研究呼吸道合胞病毒感染和冠状病毒病 (COVID-19) 感染。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,930 | In stock | |
| 5 mg | ¥ 4,790 | In stock | |
| 10 mg | ¥ 6,680 | In stock | |
| 25 mg | ¥ 9,920 | In stock | |
| 50 mg | ¥ 13,300 | In stock | |
| 100 mg | ¥ 17,800 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 3,990 | In stock |
Enzaplatovir 相关产品
| 产品描述 | Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections. |
| 别名 | 恩扎托韦, BTA-C585, BTAC585, BTA-585, BTA585, BTA 585 |
| 分子量 | 377.4 |
| 分子式 | C20H19N5O3 |
| CAS No. | 1323077-89-9 |
| Smiles | Cc1nocc1C(=O)N1CCN2C(=O)c3cccn3C[C@]12c1ccc(C)nc1 |
| 密度 | 1.46 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 150 mg/mL (397.46 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容